European Journal of Cardiovascular Medicine

morbidity in the presence of persistent antiphospholipid antibodies. Current therapeutic recommendations for thrombosis prevention in patients with APS are limited to anticoagulation with Vitamin K Antagonists (VKA) or heparins and to anti-platelet aggregating agents. Maintaining optimized anticoagulation to prevent recurrent thrombosis or bleeding remains a therapeutic challenge. Direct Oral Anticoagulants (DOACs) DOACs have been approved to prevent recurrent thrombotic events in different prothrombotic conditions, such as non- valvular atrial fibrillation, deep vein thrombosis still aim the same target and thromboprophylaxis after elective orthopedic surgery.